Trending stocks today
Kneat.com Inc (KSI-X)
CVE:KSI
4.25
0.19
(4.68%) 1d
Financials
Technical Analysis
Related posts
Most Anticipated Earnings: SLF-T, REAL-T and more Canadian Companies Reporting Earnings this Week (Nov 13-17)This summary was created by AI, based on 1 opinions in the last 12 months.
Kneat.com Inc, with the symbol KSI-X, is a software company based in Ireland that offers compliance and validation software in the life sciences business. With a growing customer base, including 8/10 of top pharma and 18/20 top bio-pharma companies, the company's outlook is very positive. It is a top pick for experts, despite a recent 17% decrease. The experts are optimistic about the future of the business, and they continue to own shares.
$4.250
Owned
- «
- ‹
- 1
- ›
- »
Kneat.com Inc(KSI-X) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Kneat.com Inc(KSI-X) Frequently Asked Questions
What is Kneat.com Inc stock symbol?
Kneat.com Inc is a Canadian stock, trading under the symbol KSI-X on the TSX Venture Exchange (KSI-CV). It is usually referred to as TSXV:KSI or KSI-X
Is Kneat.com Inc a buy or a sell?
In the last year, there was no coverage of Kneat.com Inc published on Stockchase.
Is Kneat.com Inc a good investment or a top pick?
Kneat.com Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Kneat.com Inc.
Why is Kneat.com Inc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Kneat.com Inc worth watching?
0 stock analysts on Stockchase covered Kneat.com Inc In the last year. It is a trending stock that is worth watching.
What is Kneat.com Inc stock price?
On 2021-11-12, Kneat.com Inc (KSI-X) stock closed at a price of $4.25.
Software company that is based in Ireland.
Offers compliance and validation software in life sciences business.
Currently has 8/10 of top pharma & 18/20 top bio-pharma companies as customers.
Growing customer base at a rapid rate.
Very positive on outlook of business.
Will continue to own shares.